GT201000298A - 2,6-DIAMINO-PYRIMIDIN-Z-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS - Google Patents

2,6-DIAMINO-PYRIMIDIN-Z-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS

Info

Publication number
GT201000298A
GT201000298A GT201000298A GT201000298A GT201000298A GT 201000298 A GT201000298 A GT 201000298A GT 201000298 A GT201000298 A GT 201000298A GT 201000298 A GT201000298 A GT 201000298A GT 201000298 A GT201000298 A GT 201000298A
Authority
GT
Guatemala
Prior art keywords
carboxamids
jak
diamino
inhibitors
kinasas
Prior art date
Application number
GT201000298A
Other languages
Spanish (es)
Inventor
Song Yonghong
Xu Qing
Mehrotra Mukund
Jack W Rose
Huang Wolin
Venkataramani Chandrasekar
Pandey Anjali
Shawn M Bauer
Zhaozhong J Jia
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of GT201000298A publication Critical patent/GT201000298A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON COMPUESTOS DERIVADOS DE 2,6-DIAMINO-PIRIMIDIN-5-IL-CARBOXAMIDAS, A SALES FARMACÉUTICAMENTE ACEPTABLES, TAUTÓMEROS, ESTEREOISÓMEROS, Y SU USO COMO INHIBIDORES DE JAK QUINASAS.THIS INVENTION IS RELATED TO COMPOUNDS DERIVED FROM 2,6-DIAMINO-PIRIMIDIN-5-IL-CARBOXAMIDS, TO PHARMACEUTICALLY ACCEPTABLE SALTS, TAUTOMMERS, STEREOISOMERS, AND THEIR USE AS INHIBITORS OF JAK QUINASAS.

GT201000298A 2008-04-16 2010-10-15 2,6-DIAMINO-PYRIMIDIN-Z-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS GT201000298A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4539908P 2008-04-16 2008-04-16
US4540608P 2008-04-16 2008-04-16
US4541708P 2008-04-16 2008-04-16
US12034808P 2008-12-05 2008-12-05
US12034108P 2008-12-05 2008-12-05
US12034408P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
GT201000298A true GT201000298A (en) 2014-05-07

Family

ID=43570275

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000298A GT201000298A (en) 2008-04-16 2010-10-15 2,6-DIAMINO-PYRIMIDIN-Z-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS

Country Status (18)

Country Link
AU (1) AU2009251863B2 (en)
BR (1) BRPI0910560B8 (en)
CO (1) CO6331433A2 (en)
CY (1) CY1118559T1 (en)
DK (1) DK2321283T3 (en)
ES (1) ES2597441T3 (en)
GT (1) GT201000298A (en)
HK (1) HK1158179A1 (en)
HU (1) HUE031638T2 (en)
IL (3) IL208637A (en)
LT (1) LT2321283T (en)
MX (1) MX353206B (en)
NI (1) NI201000176A (en)
NZ (1) NZ589314A (en)
PL (1) PL2321283T3 (en)
PT (1) PT2321283T (en)
SI (1) SI2321283T1 (en)
ZA (1) ZA201007045B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
KR20110025224A (en) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2807051A1 (en) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
CN105188371A (en) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk inhibitors and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN114196651B (en) * 2021-12-15 2023-06-30 中国林业科学研究院亚热带林业研究所 New application of D6 protein kinase D6PKL2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308821T3 (en) * 1997-12-15 2008-12-01 Astellas Pharma Inc. NEW DERIVATIVES OF PIRIMIDIN-5-CARBOXAMIDA.
CA2490888C (en) * 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
KR20090031787A (en) * 2006-07-21 2009-03-27 노파르티스 아게 2,4-di(arylamino)-pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
PL2321283T3 (en) 2017-01-31
DK2321283T3 (en) 2016-10-31
IL251655B (en) 2020-05-31
AU2009251863A1 (en) 2009-12-03
AU2009251863B2 (en) 2014-09-25
MX353206B (en) 2018-01-08
MX2010011464A (en) 2014-06-16
BRPI0910560B8 (en) 2023-03-21
NZ589314A (en) 2012-10-26
HK1158179A1 (en) 2012-07-13
IL251655A0 (en) 2017-06-29
LT2321283T (en) 2016-12-12
IL208637A0 (en) 2010-12-30
CO6331433A2 (en) 2011-10-20
HUE031638T2 (en) 2017-07-28
ES2597441T3 (en) 2017-01-18
SI2321283T1 (en) 2017-01-31
CY1118559T1 (en) 2017-07-12
BRPI0910560A2 (en) 2021-04-27
IL274522A (en) 2020-06-30
PT2321283T (en) 2016-10-19
IL208637A (en) 2017-04-30
BRPI0910560B1 (en) 2023-01-24
AU2009251863A2 (en) 2011-06-09
ZA201007045B (en) 2012-08-29
NI201000176A (en) 2011-08-08

Similar Documents

Publication Publication Date Title
ATE517107T1 (en) PYRROLOPYRAZINE KINASE INHIBITORS
CO6311079A2 (en) AMINODIHYDROTIAZINE DERIVATIVES AS INHIBITORS OF THE BACE ENZYME FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE522536T1 (en) PYRROLOPYRAZINE KINASE INHIBITORS
CY1118969T1 (en) Pyrimidine-2-amine compounds and their use as JAK kinase inhibitors
CR20130023A (en) PIRAZOLO [1,5-A] PYRIMIDINS FOR ANTIVIRAL TREATMENT
UY33227A (en) PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
CR11803A (en) PIRROLOPIRIDINS AS CINASE INHIBITORS
CO6321282A2 (en) PIPERIDINYLINDOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
ECSP109922A (en) PIRAZOL COMPOUNDS AND ITS USE AS RAF INHIBITORS
CO6480927A2 (en) DERIVATIVES OF IMIDAZOLIN-2-ONA 1,3-DISUSTITUTED AS CYP17 INHIBITORS.
CO6361936A2 (en) IMIDAZOPIRIDAZINACARBONITRILOS USEFUL AS QUINASE INHIBITORS
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
CR20110620A (en) DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZO-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINES AS IHNIBITORS OF THE JANUS KINASE
GT201000298A (en) 2,6-DIAMINO-PYRIMIDIN-Z-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS
UY32585A (en) NEW INDAZOL DERIVATIVES USEFUL AS INHIBITORS OF THE 3´OH QUINASA PHOSFOINOSITIDA FAMILY
ECSP10010271A (en) TIAZOL DERIVATIVES USED AS PI 3-CINASA INHIBITORS
CY1118093T1 (en) PHARMACEUTICAL FORMS CONTAINING DERIVATIVES 1- (BHTA-D-GLYCOPYRANOZYL) -2-THYNYLMETHYLBENZOLI AS SGLT ANALYPES
ATE522534T1 (en) PYRROLOPYRAZINE KINASE INHIBITORS
NI201200023A (en) DERIVATIVES OF 5-FLUOROPYRIMIDINONE
BR112012024117A2 (en) pyrrolopyrazine kinase inhibitors
MX359032B (en) Pyrrolopyrazine kinase inhibitors.
UY33226A (en) PIRROLOPIRIMIDINE COMPUTERS DEUTERATED AS INHIBITORS OF THE CDK4 / 6
EA201290632A1 (en) DERIVATIVES OF BETULINA
UY32748A (en) 2-CARBOXAMIDA-CICLOAMINO-UREAS
UY32042A (en) 2-AMINOPIRIMIDINE COMPOUNDS AS POWERFUL INHIBITORS OF HSP-90